Rare cancer of cervix uteri

Rare cancer of the cervix uteri (Orphanet code 213761) is a grouping term that encompasses uncommon malignant neoplasms arising from the uterine cervix that fall outside the typical squamous cell carcinoma and common adenocarcinoma subtypes. These rare cervical cancers include histological variants such as small cell neuroendocrine carcinoma, clear cell adenocarcinoma, adenoid basal carcinoma, adenoid cystic carcinoma, serous carcinoma, mesonephric carcinoma, melanoma of the cervix, and primary cervical sarcomas, among others. While common cervical cancers are strongly associated with persistent human papillomavirus (HPV) infection, some rare subtypes may have different etiological pathways and may not be HPV-related. These tumors primarily affect the female reproductive system, specifically the cervix, but depending on the subtype and stage, they may spread locally to the vagina, parametrium, bladder, and rectum, or metastasize to distant organs including the lungs, liver, and bones. Key symptoms are similar to those of common cervical cancers and include abnormal vaginal bleeding (postcoital, intermenstrual, or postmenopausal), unusual vaginal discharge, pelvic pain, and in advanced stages, symptoms related to involvement of adjacent organs such as urinary or bowel dysfunction. Some rare subtypes, particularly small cell neuroendocrine carcinoma, may present with paraneoplastic syndromes. Due to their rarity, these cancers are often diagnosed at more advanced stages and may carry a poorer prognosis compared to typical cervical squamous cell carcinoma. Treatment generally follows a multimodal approach including surgery (radical hysterectomy with lymph node dissection), radiation therapy, and chemotherapy, though optimal treatment protocols are not well established for many subtypes due to limited clinical trial data. For neuroendocrine subtypes, platinum-etoposide-based chemotherapy regimens are often employed. Management is best undertaken at specialized centers with experience in rare gynecological malignancies, and enrollment in clinical trials is encouraged when available.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Rare cancer of cervix uteri